Heart failure

Reading File

Asking for Preferences

Finding Sources

Searching PubMed

"heart failure" pathophysiology classification

Finding Sources

Reading File

Loading Image

I now have comprehensive content and excellent diagrams. Here is your complete overview:

Heart Failure: Definition, Types, and Pathophysiology

1. Definition

Heart failure (HF) is a clinical syndrome in which the heart cannot meet the metabolic demands of the body at normal filling pressures. It is not a single disease but a final common pathway for many cardiac insults. The preferred term is "heart failure" rather than "congestive heart failure" because pulmonary congestion is not always present - some patients experience dyspnea and reduced exercise capacity without any overt fluid overload.

Normal cardiac output is approximately 5 L/min (for a 70 kg person). In failure, output falls below this - or, in rare cases, is insufficient despite being elevated.

Textbook of Family Medicine, 9e
Katzung's Basic & Clinical Pharmacology, 16e

2. Types of Heart Failure

By Ejection Fraction

Feature	HFrEF	HFpEF
Ejection fraction	< 45-50%	> 45-50% (normal)
Primary defect	Systolic dysfunction - impaired contraction	Diastolic dysfunction - impaired relaxation/filling
Mechanism	Ventricle cannot pump effectively; fibers overstretched	Ventricle too stiff/hypertrophied to relax and fill
Drug response	Responds well to inotropes	Does NOT respond well to inotropes
Prevalence	~50% of HF cases	~50% of HF cases

Both types frequently coexist in the same patient.

Lippincott Illustrated Reviews: Pharmacology

By Output Level

Low-output failure (most common): cardiac output is reduced below normal. Typical of MI, cardiomyopathy, hypertension.
High-output failure (rare): the body's metabolic demands are so excessive that even elevated cardiac output is inadequate. Causes include hyperthyroidism, beriberi (thiamine deficiency), severe anemia, and arteriovenous malformations. This form responds poorly to standard HF drugs and requires treatment of the underlying cause.

By Side Affected

Left-sided HF: pulmonary congestion, dyspnea, orthopnea
Right-sided HF: peripheral edema, raised JVP, hepatomegaly
Biventricular failure: both sides; most chronic HF progresses here

3. Pathophysiology

3a. The Central Problem: LV Remodeling

The modern understanding moves away from a purely hemodynamic model. The central concept is left ventricular (LV) remodeling - progressive dilation and distortion of LV geometry with loss of function. This can be triggered by:

Coronary artery disease / myocardial infarction
Hypertension
Valvular heart disease
Diabetes, alcoholism, congenital defects, anemia

Remodeling is potentially reversible with appropriate treatment.

At the cellular level, key changes include:

Altered calcium flux in myocytes (impaired contraction/relaxation)
Down-regulation of beta-adrenergic receptors
Shift from fatty acid oxidation to glycolysis
Matrix metalloprotease (MMP) activation -> collagen deposition and fibrosis
Myocyte apoptosis (programmed cell death)
Textbook of Family Medicine, 9e

3b. Neurohormonal Activation (The Vicious Cycle)

Once cardiac output falls, two major compensatory systems activate:

Sympathetic Nervous System (SNS)

Baroreceptors sense low blood pressure -> vasomotor center increases sympathetic outflow
Effect: tachycardia, increased contractility, vasoconstriction
Vasoconstriction increases afterload, which further reduces ejection fraction - creating a downward spiral
Chronic catecholamine excess is directly toxic to myocytes (via cAMP-dependent calcium overload)
Beta-adrenergic receptors are progressively down-regulated, reducing sensitivity

Renin-Angiotensin-Aldosterone System (RAAS)

Low renal blood flow triggers renin release -> angiotensin II -> aldosterone
Effects: vasoconstriction (more afterload), sodium and water retention (more preload), cardiac fibrosis
Angiotensin II promotes myocyte apoptosis, hypertrophy, and fibrosis
Aldosterone "escapes" ACE inhibitor suppression - which is why aldosterone blockers (e.g. spironolactone) are needed in addition to ACE inhibitors/ARBs

Endothelin-1 from dysfunctional endothelium adds further vasoconstriction.

Compensatory responses in heart failure showing SNS and RAAS activation

Compensatory responses in HF: SNS and RAAS activation (Katzung's Basic & Clinical Pharmacology, 16e)

Katzung's Basic & Clinical Pharmacology, 16e

3c. The Four Major Compensatory Mechanisms

Increased sympathetic activity: increased heart rate and contractility, vasoconstriction to maintain perfusion pressure. Short-term benefit, long-term harm.
RAAS activation: sodium/water retention expands blood volume and increases preload (Starling mechanism). If the heart cannot pump the extra volume forward, venous pressure rises and edema results.
Natriuretic peptides (ANP, BNP): released in response to increased wall stretch. These are the body's counter-regulatory response - they promote vasodilation, natriuresis, and inhibit renin/aldosterone. However, in established HF, the heart becomes resistant to natriuretic peptides (via receptor desensitization and cGMP pathway impairment), blunting this protective effect. This is why BNP levels are actually elevated in HF - the hormone is being produced but not working.
Myocardial hypertrophy: Initially, wall thickening maintains contractility. Over time, hypertrophy leads to stiffness (diastolic dysfunction) and the fibers become overstretched (systolic dysfunction).

Additional pathological features:

Inflammation and oxidative stress: tissue hypoperfusion and neurohormonal activation cause mitochondrial dysfunction, cytokine release, and further myocyte death.

Cardiovascular consequences of HF showing edema formation pathway

The vicious cycle of HF: how reduced cardiac output leads to edema through RAAS and sympathetic activation (Lippincott Illustrated Reviews: Pharmacology)

Lippincott Illustrated Reviews: Pharmacology

4. Classification Systems

NYHA Functional Classification (symptom-based)

Class	Description
I	No symptoms with ordinary activity
II	Mild symptoms (dyspnea) with moderate exertion
III	Marked limitation; symptoms with minimal activity
IV	Symptoms at rest; unable to carry on any activity

ACC/AHA Staging System (disease progression-based)

This newer system accounts for risk factors and structural disease, not just symptoms. Patients move through stages but cannot move backward (unlike NYHA class, which can improve).

Stage	Description	Approx. US population
A	At risk (HTN, DM, IHD, family history) but no LV dysfunction or symptoms	>60 million
B	Structural LV dysfunction but asymptomatic (~NYHA I)	~10 million
C	Structural disease + current or prior symptoms (~NYHA II-III)	~5 million
D	Refractory HF, symptoms at rest (~NYHA IV)	~200,000

Textbook of Family Medicine, 9e

5. Clinical Consequences (Overview)

The primary signs and symptoms stem from two processes:

Forward failure (reduced output):

Fatigue and decreased exercise tolerance
Tachycardia
Cool, clammy extremities

Backward failure (increased filling pressures):

Left heart: pulmonary congestion, dyspnea, orthopnea, paroxysmal nocturnal dyspnea
Right heart: peripheral edema, raised JVP, hepatomegaly

Key lab/diagnostic markers: elevated BNP/NT-proBNP (reflect wall stress), ECG changes, cardiomegaly on CXR, reduced EF on echocardiogram.

Summary Diagram of Pathophysiology

Cardiac injury (MI, HTN, valvular disease, etc.)
            ↓
    LV dysfunction + remodeling
            ↓
      ↓ Cardiac output
       /           \
 ↑ SNS          ↓ Renal blood flow
 activation          ↓
     \           ↑ Renin → ↑ Ang II → ↑ Aldosterone
      \               ↓
       ↑ HR, contractility, vasoconstriction
       ↑ Na+ and water retention
             ↓
       ↑ Preload + ↑ Afterload
             ↓
      Further ↓ EF and ↓ CO
             ↓
       Edema, dyspnea, fatigue
       (Symptoms of HF)

Key takeaway for exam purposes: HF pathophysiology is driven by a neurohormonal vicious cycle (SNS + RAAS), not just a pump problem. This is why the most effective treatments - ACE inhibitors, beta-blockers, aldosterone antagonists, and ARNIs - all target this neurohormonal axis rather than simply trying to boost cardiac output.

Sources: Katzung's Basic & Clinical Pharmacology 16e, Lippincott Illustrated Reviews: Pharmacology, Textbook of Family Medicine 9e

This is a shared conversation. Sign in to Orris to start your own chat.